Treatment of calmodulinopathy with verapamil

Gregory Webster; Zachary J. Schoppen; Alfred L. George

doi:10.1136/bcr-2017-220568

Treatment of calmodulinopathy with verapamil

Gregory Webster^*, Zachary J. Schoppen, Alfred L. George

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Pathological variants in genes encoding calmodulin are associated with severe clinical presentations, including recurrent ventricular fibrillation and sudden death. Beta-receptor antagonists (beta-blockers) and sodium-channel antagonists have been reported as pharmacotherapies in these disorders; however, recent data have demonstrated the importance of derangements in calcium channel inactivation. We report a sustained attempt to use calcium-channel antagonists to treat calmodulinopathy and review the treatment strategies reported in the literature to date.

Original language	English (US)
Article number	bcr-2017-220568
Journal	BMJ case reports
Volume	2017
DOIs	https://doi.org/10.1136/bcr-2017-220568
State	Published - 2017

Funding

Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences, Grant Number KL2TR001424. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Keywords

arrhythmias
cardiovascular medicine

ASJC Scopus subject areas

General Medicine

Access to Document

10.1136/bcr-2017-220568

Cite this

@article{02bb8163c0b94684b6950b6b889ba1a7,

title = "Treatment of calmodulinopathy with verapamil",

abstract = "Pathological variants in genes encoding calmodulin are associated with severe clinical presentations, including recurrent ventricular fibrillation and sudden death. Beta-receptor antagonists (beta-blockers) and sodium-channel antagonists have been reported as pharmacotherapies in these disorders; however, recent data have demonstrated the importance of derangements in calcium channel inactivation. We report a sustained attempt to use calcium-channel antagonists to treat calmodulinopathy and review the treatment strategies reported in the literature to date.",

keywords = "arrhythmias, cardiovascular medicine",

author = "Gregory Webster and Schoppen, {Zachary J.} and George, {Alfred L.}",

note = "Publisher Copyright: {\textcopyright} 2017 BMJ Publishing Group Ltd.",

year = "2017",

doi = "10.1136/bcr-2017-220568",

language = "English (US)",

volume = "2017",

journal = "BMJ case reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Treatment of calmodulinopathy with verapamil

AU - Webster, Gregory

AU - Schoppen, Zachary J.

AU - George, Alfred L.

PY - 2017

Y1 - 2017

N2 - Pathological variants in genes encoding calmodulin are associated with severe clinical presentations, including recurrent ventricular fibrillation and sudden death. Beta-receptor antagonists (beta-blockers) and sodium-channel antagonists have been reported as pharmacotherapies in these disorders; however, recent data have demonstrated the importance of derangements in calcium channel inactivation. We report a sustained attempt to use calcium-channel antagonists to treat calmodulinopathy and review the treatment strategies reported in the literature to date.

AB - Pathological variants in genes encoding calmodulin are associated with severe clinical presentations, including recurrent ventricular fibrillation and sudden death. Beta-receptor antagonists (beta-blockers) and sodium-channel antagonists have been reported as pharmacotherapies in these disorders; however, recent data have demonstrated the importance of derangements in calcium channel inactivation. We report a sustained attempt to use calcium-channel antagonists to treat calmodulinopathy and review the treatment strategies reported in the literature to date.

KW - arrhythmias

KW - cardiovascular medicine

UR - http://www.scopus.com/inward/record.url?scp=85027125920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027125920&partnerID=8YFLogxK

U2 - 10.1136/bcr-2017-220568

DO - 10.1136/bcr-2017-220568

M3 - Article

C2 - 28784889

AN - SCOPUS:85027125920

SN - 1757-790X

VL - 2017

JO - BMJ case reports

JF - BMJ case reports

M1 - bcr-2017-220568

ER -

Treatment of calmodulinopathy with verapamil

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this